知镜 Cognispect · 医学文献与研究工作台

Anti-TNF therapy attenuates the diagnostic utility of leucine-rich α2-Glycoprotein 1 for endoscopic activity in ulcerative colitis.

Dejima A, Takatori H, Miyazawa M, Okafuji H, Hayashi T, Seki A, Nio K, Iida N, Yamada S, Shimakami T, Toyama T, Yamashita T.
Therapeutic advances in gastroenterology · 2026-09-10 · PMID 42729529

文献摘要

Background Serum leucine-rich α2-glycoprotein1 (LRG1) is a promising biomarker for mucosal inflammation in ulcerative colitis (UC). However, because systemic LRG1 expression is partly tumor necrosis factor-α (TNF-α)-dependent, anti-TNF therapy may pharmacologically suppress its levels independently of mucosal status. Objectives To evaluate whether anti-TNF therapy is associated with false-negative serum LRG1 results, attenuates diagnostic accuracy for endoscopic activity (MES ≧ 2), and impairs diagnostic granularity to differentiate strict healing targets (MES 0 vs. 1) compared to other therapies. Design A retrospective, single-center diagnostic accuracy study conducted in accordance with the STARD 2015 guidelines. Methods We analyzed 127 paired colonoscopy-LRG1 evaluations (49 under anti-TNF, 78 without) from 50 patients receiving advanced therapies (April 2021-March 2025). Endoscopic activity was defined as Mayo Endoscopic Subscore (MES) ≥2. Diagnostic performance was evaluated using ROC analysis; AUC differences were compared using a cluster bootstrap approach. Factors associated with false-negative LRG1 ( Results Overall, LRG1 demonstrated satisfactory discrimination (AUC 0.81), but performed significantly lower under anti-TNF than non-anti-TNF therapy (AUC 0.44 vs. 0.91; ΔAUC=0.46). Among active evaluations, 45% (24/53) showed false-negatives. Anti-TNF was a strong independent predictor of false-negatives (OR 9.3, 95% CI 1.68-51.9), while JAK inhibitor use was protective (OR 0.09, 95% CI 0.01-0.80, P Conclusion Anti-TNF therapy may selectively attenuate serum LRG1 performance, potentially causing frequent false-negatives and obscuring the distinction between complete healing (MES 0) and mild residual inflammation (MES 1). Clinicians must consider the therapeutic context when interpreting LRG1 for disease monitoring.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。